Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339753 | 0.97 | THRB (0.47) | THRBLMNATP53GAAMEN1 | |
| SCHEMBL5466880 | 0.96 | THRB (0.53) | THRBLMNATP53 | |
| SCHEMBL5464748 | 0.95 | THRB (0.45) | THRBLMNATP53 | |
| SCHEMBL5356562 | 0.92 | THRB (0.52) | THRBLMNATP53GAAMEN1 | |
| SCHEMBL5356010 | 0.91 | LMNA (0.46) | THRBLMNATP53TOP1 | |
| SCHEMBL5350679 | 0.89 | LMNA (0.44) | THRBLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL14339757 | 0.88 | LMNA (0.44) | THRBLMNAGAAALDH1A1TOP1 | |
| SCHEMBL5365609 | 0.88 | RXFP1 (0.47) | LMNATP53MEN1KMT2AKDM4E | |
| SCHEMBL14339573 | 0.88 | LMNA (0.45) | THRBLMNAKDM4ETOP1 | |
| SCHEMBL5360224 | 0.87 | THRB (0.44) | THRBLMNATP53GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | THRB 4510/4885LMNA 4460/4885TP53 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.